少なくとも1つのトール様受容体7またはトール様受容体8アゴニストおよびトール様受容体4アゴニストを含む免疫賦活性組成物

Japanese Patent JP2007514725

A

An immunostimulant composition (A) containing at least one toll-like receptor 7 or toll-like receptor 8 agonist (I) additionally contains a toll-like receptor 4 agonist (II). ACTIVITY : Immunostimulant; Antibacterial; Virucide; Hepatotropic; Antiinflammatory; Anti-HIV; Cytostatic; Antitubercular; Protozoacide. In tests in mice, subcutaneous injection of a composition containing 20 mu g Tat protein (as antigen), 5 mu g 4-amino-2-ethoxymethyl-alpha ,alpha -dimethyl-1H-imidazo-(4,5-c)-quinoline-1-ethanol(Ia)and 5 mu g ER804057 (IIa) gave an IgG1/IgG2a ratio 32 days later of 0.9, compared with 176.2 for Tat alone, 1.3 for Tat plus (Ia) and 3.5 for Tat plus (IIa), demonstrating that the combination of (Ia) and (IIa) orientated the immune response strongly towards the Th1 (rather than Th2) type. MECHANISM OF ACTION : Toll-like receptor 7 agonist; toll-like receptor 7 agonist; toll-like receptor 4 agonist.

Nikola Bourdan
Jean Enslet

JP2006544506A

June 07, 2007

December 20, 2004

Click for automatic bibliography generation  

SANOFI PASTEUR

A61K31/6615; A61K31/4745; A61K31/685; A61K39/00; A61K39/12; A61K39/39; A61K45/06; A61K47/22; A61K47/24; A61P31/18; A61P37/04; A61P43/00

JP2002535411A	2002-10-22
JP2007505827A	2007-03-15
JP2005519990A	2005-07-07
JP2006512391A	2006-04-13

WO2003086280A2

2003-10-23

JPN5006020406, Ｖａｃｃｉｎｅ, 2003, Ｖｏｌ．２１, ｐ．９６１−９７０
JPN5006020407, ＶＡＳＩＬＡＫＯＳ　Ｊ　Ｐ, ＣＥＬＬＵＬＡＲ　ＩＭＭＵＮＯＬＯＧＹ, 20000825, Ｖ２０４　Ｎ１, Ｐ６４−７４, US, ＡＣＡＤＥＭＩＣ　ＰＲＥＳＳ

Mitsuo Tanaka
Tadayuki Motoyama
Kenji Tomita

Previous Patent: 抗腫瘍薬の形態でのスーパーオキシドジスムターゼ及びグルタチオンレダ�...

Next Patent: ４−アミノ−５−クロロ−２−メトキシ−Ｎ−（１−アザビシクロ［３．�...